Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Owning CSL Ltd (ASX: CSL) shares over the past decade has been very rewarding, with good dividend growth and enormous capital growth. As shown on the chart below, the CSL share price has soared more than 200% in the past decade.

In my view, CSL may be the most impressive business on the ASX, with a market capitalisation of $100 billion. Its growth and global success are commendable.

Long-term shareholders are receiving much bigger dividends and are predicted to see even larger payments.

Let's have a look at how the CSL dividend could grow between now and the 2029 financial year.

Man holding Australian dollar notes, symbolising dividends.

Image source: Getty Images

This year, FY25

We're already close to halfway through the CSL 2025 financial year, so it won't be long before shareholders learn the FY25 interim dividend payment with the half-year result, which is expected in February 2025.

As for the annual dividend per share, UBS is currently forecasting that the CSL dividend could jump by 12% to US$2.96 per share. At the current CSL share price, that would represent a dividend yield of close to 1.7%.

UBS also considers the "possibility of a less vaccine-friendly US administration", which could impact CSL's vaccine business.

Next year, FY26

In the 2026 financial year, UBS is expecting CSL's profit to rise by more than 10%, and this can help the company's dividend rise too.

UBS is projecting that the CSL dividend could jump by another 12% to US$3.31 per share. That would represent a dividend yield of close to 1.9%. Not huge, but it's growing at a good pace.

After that, FY27

The 2027 financial year could see the business continue to grow its profit and dividend at a pleasing double-digit speed.

UBS projects that owners of CSL shares could receive an annual dividend per share of US$3.71, an increase of 12%. At the current valuation, that would represent a dividend yield of 2.1%.

Then, FY28

As an ASX healthcare share, it's quite possible that the company could deliver consistent profit growth over this period of time.

According to UBS, in the 2028 financial year, CSL could deliver a dividend increase of close to 12%, taking the annual payment to US$4.15. At the current CSL share price, that would represent a dividend yield of 2.35%.

Finally, FY29

The 2029 financial year is projected to be the best year of all – it could see yet another double-digit increase in percentage terms of both profit and dividend.

UBS forecasts that CSL's dividend could increase by another 12% in FY29 to US$4.65. At the current valuation, this payout would mean a dividend yield of 2.6%.

A 2.6% dividend yield isn't huge, but it shows how the dividend could scale upwards. Rising profit could also be exactly what investors want to see with CSL shares.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

2 classy ASX healthcare stocks to buy before the next market surge

If sentiment shifts, these global powerhouses could lead the rally.

Read more »

Two people jump and high five above a city skyline.
Healthcare Shares

Why rebounding Telix shares could still rise 40%

Bell Potter doesn't think it is too late to buy this stock.

Read more »

Female in elegant outfit smiling and gesturing victory with hands.
Healthcare Shares

Are Telix shares a buy after flying 40% higher in March?

Telix shares are up another 5.3% on Tuesday.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Down 30% today, is it time to buy into this beaten-down biotech share?

While there's been bad news, this company has more irons in the fire.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

What's the impact of US tariffs on Aussie drugmakers CSL and Mayne Pharma?

Is the US' bark worse than its bite?

Read more »

Health professional working on his laptop.
Healthcare Shares

Mesoblast shares are back in the red on Tuesday. Here's why

Mesoblast shares slip despite another strong quarterly sales update from Ryoncil.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Earnings Results

Why are Telix shares jumping 8% today?

The radiopharmaceuticals company's shares are starting the week strongly.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Mesoblast shares: Ryoncil® underpins strong earnings growth

Mesoblast shares are in focus as Ryoncil® delivers nearly US$100m in sales since launch, fueling future growth initiatives.

Read more »